C-POST protocol update: A Phase 3, randomized, double-blind study of adjuvant cemiplimab versus placebo post surgery and radiation therapy in patients with high-risk cutaneous squamous cell carcinoma
Main Article Content
Keywords
cemiplimab
References
2. Stratigos AJ et al. Eur J Cancer. 2015;51:1989–2007.
3. Porceddu SV et al. J Clin Oncol. 2018;36:1275–1283.
4. Regeneron Pharmaceuticals, Inc. LIBTAYO® (cemiplimab-rwlc) injection, for intravenous use [US prescribing information]; 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761097s007lbl.pdf. AccessedJanuary 28, 2022.
5. Health Canada. LIBTAYO® – Notice of compliance with conditions – qualifying notice; 2019. Available at: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/notice-compliance/conditions/libtayonotice-compliance-conditions-218718.html. Accessed January 28, 2022.
6. Brazilian Health Authority – ANVISA. Libtayo (Cemiplimab): new indication; 2021. Available at: https://www.gov.br/anvisa/pt-br/assuntos/medicamentos/novos-medicamentos-e-indicacoes/libtayo-cemiplimabe-nova-indicacao. Accessed January 28, 2022.
7. Ministry of Health Israel. The Israeli Drug Registry – LIBTAYO; 2019. Available at: https://israeldrugs.health.gov.il/#!/medDetails/164%2099%2036023%2000. Accessed January 28, 2022.
8. Regeneron Pharmaceuticals, Inc. Libtayo® (cemiplimab) approved by the European Commission as the first immunotherapy indicated for patients with advanced basal cell carcinoma; 2021. Available at: https://www.prnewswire.com/news-releases/libtayo-cemiplimabapproved-by-the-european-commission-as-the-first-immunotherapyindicated-for-patients-with-advanced-basal-cell-carcinoma-301319988.html. Accessed January 28, 2022.
9. Migden MR et al. N Engl J Med. 2018;379:341–351.
10. Migden MR et al. Lancet Oncol. 2020;21:294–305.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.